{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:21:03Z","timestamp":1770445263509,"version":"3.49.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T00:00:00Z","timestamp":1471824000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s11940-016-0429-y","type":"journal-article","created":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T02:48:14Z","timestamp":1471834094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Management of Narcolepsy"],"prefix":"10.1007","volume":"18","author":[{"given":"Lucie","family":"Barateau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9gis","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Dauvilliers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,22]]},"reference":[{"key":"429_CR1","unstructured":"AASM: American Academy of Sleep Medicine. ICSD-3: International Classification of Sleep Disorders, 3rd ed. American Academy of Sleep Medicine. 2014. This recent classification is the reference for the diagnosis of sleep disorders worldwide."},{"key":"429_CR2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1474-4422(14)70075-4","volume":"13","author":"M Partinen","year":"2014","unstructured":"Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol. 2014;13:600\u201313.","journal-title":"Lancet Neurol"},{"key":"429_CR3","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1212\/WNL.58.12.1826","volume":"58","author":"MM Ohayon","year":"2002","unstructured":"Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology. 2002;58:1826\u201333.","journal-title":"Neurology"},{"key":"429_CR4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","volume":"369","author":"Y Dauvilliers","year":"2007","unstructured":"Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369:499\u2013511.","journal-title":"Lancet"},{"key":"429_CR5","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","volume":"373","author":"TE Scammell","year":"2015","unstructured":"Scammell TE. Narcolepsy. N Engl J Med. 2015;373:2654\u201362. A recent review article about symptoms and diagnosis of narcolepsy.","journal-title":"N Engl J Med"},{"key":"429_CR6","unstructured":"AASM. ICSD-2: International Classification of Sleep Disorders, 2d ed. American Academy of Sleep Medicine. 2005."},{"key":"429_CR7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.5664\/jcsm.2922","volume":"9","author":"LM Trotti","year":"2013","unstructured":"Trotti LM, Staab BA, Rye DB. Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. J Clin Sleep Med. 2013;9:789\u201395.","journal-title":"J Clin Sleep Med"},{"key":"429_CR8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.5665\/sleep.2080","volume":"35","author":"O Andlauer","year":"2012","unstructured":"Andlauer O, Moore H, Hong S-C, Dauvilliers Y, Kanbayashi T, Nishino S, et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep. 2012;35:1247\u201355F.","journal-title":"Sleep"},{"key":"429_CR9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40263-016-0337-4","volume":"30","author":"L Barateau","year":"2016","unstructured":"Barateau L, Lopez R, Dauvilliers Y. Treatment options for narcolepsy. CNS Drugs. 2016;30:369\u201379. A recent review about management strategies in narcolepsy.","journal-title":"CNS Drugs"},{"key":"429_CR10","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1093\/sleep\/17.suppl_8.S107","volume":"17","author":"M Billiard","year":"1994","unstructured":"Billiard M, Besset A, Montplaisir J, Laffont F, Goldenberg F, Weill JS, et al. Modafinil: a double-blind multicentric study. Sleep. 1994;17:S107\u201312.","journal-title":"Sleep"},{"key":"429_CR11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.49.2.444","volume":"49","author":"RJ Broughton","year":"1997","unstructured":"Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49:444\u201351.","journal-title":"Neurology"},{"key":"429_CR12","doi-asserted-by":"crossref","unstructured":"Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000;54:1166\u201375.","DOI":"10.1212\/WNL.54.5.1166"},{"key":"429_CR13","doi-asserted-by":"crossref","unstructured":"Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann. Neurol. 1998;43:88\u201397.","DOI":"10.1002\/ana.410430115"},{"key":"429_CR14","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.neuroscience.2005.02.003","volume":"132","author":"JP Wisor","year":"2005","unstructured":"Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience. 2005;132:1027\u201334.","journal-title":"Neuroscience"},{"key":"429_CR15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00002826-200309000-00009","volume":"26","author":"JRL Schwartz","year":"2003","unstructured":"Schwartz JRL, Feldman NT, Bogan RK, Nelson MT, Hughes RJ. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol. 2003;26:252\u20137.","journal-title":"Clin Neuropharmacol"},{"key":"429_CR16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hup.579","volume":"19","author":"BE Leonard","year":"2004","unstructured":"Leonard BE, McCartan D, White J, King DJ. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol. 2004;19:151\u201380.","journal-title":"Hum Psychopharmacol"},{"key":"429_CR17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.sleep.2003.11.002","volume":"5","author":"U.S. Xyrem Multicenter Study Group","year":"2004","unstructured":"U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5:119\u201323.","journal-title":"Sleep Med"},{"key":"429_CR18","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/sleep\/29.7.939","volume":"29","author":"J Black","year":"2006","unstructured":"Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29:939\u201346.","journal-title":"Sleep"},{"key":"429_CR19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5664\/jcsm.27549","volume":"5","author":"YG Wang","year":"2009","unstructured":"Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med. 2009;5:365\u201371.","journal-title":"J Clin Sleep Med"},{"key":"429_CR20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","volume":"30","author":"J-S Lin","year":"2008","unstructured":"Lin J-S, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-\/- mice and patients. Neurobiol Dis. 2008;30:74\u201383.","journal-title":"Neurobiol Dis"},{"key":"429_CR21","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","volume":"12","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12:1068\u201375. A randomized trial that showed the efficacy and safety of a new drug in narcolepsy, that activates histamine neurons.","journal-title":"Lancet Neurol"},{"key":"429_CR22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/sleep\/16.3.203","volume":"16","author":"MM Mitler","year":"1993","unstructured":"Mitler MM, Hajdukovic R, Erman MK. Treatment of narcolepsy with methamphetamine. Sleep. 1993;16:306\u201317.","journal-title":"Sleep"},{"key":"429_CR23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/sleep\/28.6.667","volume":"28","author":"RR Auger","year":"2005","unstructured":"Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL. Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. Sleep. 2005;28:667\u201372.","journal-title":"Sleep"},{"key":"429_CR24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0140-6736(91)92966-6","volume":"337","author":"B Alvarez","year":"1991","unstructured":"Alvarez B, Dahlitz M, Grimshaw J, Parkes JD. Mazindol in long-term treatment of narcolepsy. Lancet Lond Engl. 1991;337:1293\u20134.","journal-title":"Lancet Lond Engl"},{"key":"429_CR25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.sleep.2012.07.008","volume":"14","author":"N Nittur","year":"2013","unstructured":"Nittur N, Konofal E, Dauvilliers Y, Franco P, Leu-Semenescu S, Cock VCD, et al. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med. 2013;14:30\u20136.","journal-title":"Sleep Med"},{"key":"429_CR26","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1468-1331.2006.01473.x","volume":"13","author":"M Billiard","year":"2006","unstructured":"Billiard M, Bassetti C, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G, et al. EFNS guidelines on management of narcolepsy. Eur J Neurol. 2006;13:1035\u201348.","journal-title":"Eur J Neurol"},{"key":"429_CR27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2014.10.002","volume":"16","author":"MJ Thorpy","year":"2015","unstructured":"Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16:9\u201318. A recent article with recommendations to manage narcolepsy symptoms.","journal-title":"Sleep Med"},{"key":"429_CR28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2869.2011.00991.x","volume":"21","author":"M Lecendreux","year":"2012","unstructured":"Lecendreux M, Bruni O, Franco P, Gringras P, Konofal E, Nevsimalova S, et al. Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy. J Sleep Res. 2012;21:481\u20133.","journal-title":"J Sleep Res"},{"key":"429_CR29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/11315280-000000000-00000","volume":"29","author":"M Darwish","year":"2009","unstructured":"Darwish M, Kirby M, Hellriegel ET, Robertson P. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig. 2009;29:613\u201323.","journal-title":"Clin Drug Investig"},{"key":"429_CR30","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1592\/phco.22.9.798.34063","volume":"22","author":"LA Borgen","year":"2002","unstructured":"Borgen LA, Cook HN, Hornfeldt CS, Fuller DE. Sodium oxybate (GHB) for treatment of cataplexy. Pharmacotherapy. 2002;22:798\u20139. discussion 799.","journal-title":"Pharmacotherapy"},{"key":"429_CR31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.smrv.2011.09.001","volume":"16","author":"R Boscolo-Berto","year":"2012","unstructured":"Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2012;16:431\u201343.","journal-title":"Sleep Med Rev"},{"key":"429_CR32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/sleep\/9.1.260","volume":"9","author":"MM Mitler","year":"1986","unstructured":"Mitler MM, Shafor R, Hajdukovich R, Timms RM, Browman CP. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep. 1986;9:260\u20134.","journal-title":"Sleep"},{"key":"429_CR33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00004691-199001000-00008","volume":"7","author":"MM Mitler","year":"1990","unstructured":"Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. J Clin Neurophysiol. 1990;7:93\u2013118.","journal-title":"J Clin Neurophysiol"},{"key":"429_CR34","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.290.6476.1167","volume":"290","author":"J Shindler","year":"1985","unstructured":"Shindler J, Schachter M, Brincat S, Parkes JD. Amphetamine, mazindol, and fencamfamin in narcolepsy. Br Med J (Clin Res Ed). 1985;290:1167\u201370.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"429_CR35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.5665\/sleep.5530","volume":"39","author":"L Barateau","year":"2016","unstructured":"Barateau L, Jaussent I, Lopez R, Boutrel B, Leu-Semenescu S, Arnulf I, et al. Smoking, alcohol, drug use, abuse and dependence in narcolepsy and idiopathic hypersomnia: a case-control study. Sleep. 2016;39:573\u201380.","journal-title":"Sleep"},{"key":"429_CR36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/14656566.2013.783021","volume":"14","author":"R Lopez","year":"2013","unstructured":"Lopez R, Dauvilliers Y. Pharmacotherapy options for cataplexy. Expert Opin Pharmacother. 2013;14:895\u2013903.","journal-title":"Expert Opin Pharmacother"},{"key":"429_CR37","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/sleep\/24.4.385","volume":"24","author":"AE Rogers","year":"2001","unstructured":"Rogers AE, Aldrich MS, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep. 2001;24:385\u201391.","journal-title":"Sleep"},{"key":"429_CR38","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/sleep\/24.7.813","volume":"24","author":"HP Dongen Van","year":"2001","unstructured":"Van Dongen HP, Price NJ, Mullington JM, Szuba MP, Kapoor SC, Dinges DF. Caffeine eliminates psychomotor vigilance deficits from sleep inertia. Sleep. 2001;24:813\u20139.","journal-title":"Sleep"},{"key":"429_CR39","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nrneurol.2014.97","volume":"10","author":"Y Dauvilliers","year":"2014","unstructured":"Dauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. Cataplexy\u2014clinical aspects, pathophysiology and management strategy. Nat Rev Neurol. 2014;10:386\u201395. A recent review of pathophysiology of cataplexy, and treatment options of this pathognomonic symptom of narcolepsy type 1.","journal-title":"Nat Rev Neurol"},{"key":"429_CR40","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.sleep.2008.05.012","volume":"10","author":"AM Husain","year":"2009","unstructured":"Husain AM, Ristanovic RK, Bogan RK. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med. 2009;10:661\u20133.","journal-title":"Sleep Med"},{"issue":"Suppl 1","key":"429_CR41","first-page":"217","volume":"5","author":"M Smith","year":"1996","unstructured":"Smith M, Parkes J, Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res. 1996;5 Suppl 1:217.","journal-title":"J Sleep Res"},{"key":"429_CR42","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1212\/01.wnl.0000175978.61048.62","volume":"65","author":"R Poryazova","year":"2005","unstructured":"Poryazova R, Siccoli M, Werth E, Bassetti CL. Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology. 2005;65:967\u20138.","journal-title":"Neurology"},{"key":"429_CR43","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1212\/WNL.44.4.707","volume":"44","author":"J Frey","year":"1994","unstructured":"Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology. 1994;44:707\u20139.","journal-title":"Neurology"},{"key":"429_CR44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/sleep\/9.2.371","volume":"9","author":"N Langdon","year":"1986","unstructured":"Langdon N, Shindler J, Parkes JD, Bandak S. Fluoxetine in the treatment of cataplexy. Sleep. 1986;9:371\u20133.","journal-title":"Sleep"},{"key":"429_CR45","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/00325481.2015.1081046","volume":"127","author":"DJ Walker","year":"2015","unstructured":"Walker DJ, Mason O, Clemow DB, Day KA. Atomoxetine treatment in adults with attention-deficit\/hyperactivity disorder. Postgrad Med. 2015;127:686\u2013701.","journal-title":"Postgrad Med"},{"key":"429_CR46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp.43.2.171","volume":"43","author":"M Schachter","year":"1980","unstructured":"Schachter M, Parkes JD. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry. 1980;43:171\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"429_CR47","doi-asserted-by":"crossref","first-page":"955","DOI":"10.5664\/jcsm.3004","volume":"9","author":"T Roth","year":"2013","unstructured":"Roth T, Dauvilliers Y, Mignot E, Montplaisir J, Paul J, Swick T, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med. 2013;9:955\u201365.","journal-title":"J Clin Sleep Med"},{"key":"429_CR48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/sleep\/15.3.212","volume":"15","author":"MJ Thorpy","year":"1992","unstructured":"Thorpy MJ, Snyder M, Aloe FS, Ledereich PS, Starz KE. Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep. 1992;15:212\u20136.","journal-title":"Sleep"},{"key":"429_CR49","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.sleep.2012.10.006","volume":"14","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Jennum P, Plazzi G. Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. Sleep Med. 2013;14:775\u201381.","journal-title":"Sleep Med"},{"key":"429_CR50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.sleep.2014.09.011","volume":"16","author":"IR McGrane","year":"2015","unstructured":"McGrane IR, Leung JG, St Louis EK, Boeve BF. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015;16:19\u201326.","journal-title":"Sleep Med"},{"key":"429_CR51","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2869.1993.tb00093.x","volume":"2","author":"C Schenck","year":"1993","unstructured":"Schenck C, Hurwitz T, Mahowald M. Symposium: normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. J Sleep Res. 1993;2:224\u201331.","journal-title":"J Sleep Res"},{"key":"429_CR52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamaneurol.2015.2904","volume":"73","author":"J Liebenthal","year":"2016","unstructured":"Liebenthal J, Valerio J, Ruoff C, Mahowald M. A case of rapid eye movement sleep behavior disorder in Parkinson disease treated with sodium oxybate. JAMA Neurol. 2016;73:126\u20137.","journal-title":"JAMA Neurol"},{"key":"429_CR53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/WNF.0b013e318193e394","volume":"32","author":"JM Shneerson","year":"2009","unstructured":"Shneerson JM. Successful treatment of REM sleep behavior disorder with sodium oxybate. Clin Neuropharmacol. 2009;32:158\u20139.","journal-title":"Clin Neuropharmacol"},{"key":"429_CR54","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.sleep.2013.03.002","volume":"14","author":"MM Ohayon","year":"2013","unstructured":"Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med. 2013;14:488\u201392.","journal-title":"Sleep Med"},{"key":"429_CR55","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/oby.2003.156","volume":"11","author":"SW Kok","year":"2003","unstructured":"Kok SW, Overeem S, Visscher TLS, Lammers GJ, Seidell JC, Pijl H, et al. Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res. 2003;11:1147\u201354.","journal-title":"Obes Res"},{"key":"429_CR56","doi-asserted-by":"crossref","first-page":"e38977","DOI":"10.1371\/journal.pone.0038977","volume":"7","author":"Y Dauvilliers","year":"2012","unstructured":"Dauvilliers Y, Jaussent I, Krams B, Scholz S, Lado S, Levy P, et al. Non-dipping blood pressure profile in narcolepsy with cataplexy. PLoS One. 2012;7:e38977.","journal-title":"PLoS One"},{"key":"429_CR57","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1212\/WNL.0000000000000793","volume":"83","author":"V Donadio","year":"2014","unstructured":"Donadio V, Liguori R, Vandi S, Pizza F, Dauvilliers Y, Leta V, et al. Lower wake resting sympathetic and cardiovascular activities in narcolepsy with cataplexy. Neurology. 2014;83:1080\u20136.","journal-title":"Neurology"},{"key":"429_CR58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11325-009-0283-1","volume":"14","author":"NT Feldman","year":"2010","unstructured":"Feldman NT. Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath Schlaf Atm. 2010;14:77\u20139.","journal-title":"Sleep Breath Schlaf Atm"},{"key":"429_CR59","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp.2008.161588","volume":"80","author":"Y Dauvilliers","year":"2009","unstructured":"Dauvilliers Y, Paquereau J, Bastuji H, Drouot X, Weil J-S, Viot-Blanc V. Psychological health in central hypersomnias: the French Harmony study. J Neurol Neurosurg Psychiatry. 2009;80:636\u201341.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"429_CR60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.genhosppsych.2009.08.007","volume":"32","author":"HAD Fortuyn","year":"2010","unstructured":"Fortuyn HAD, Lappenschaar MA, Furer JW, Hodiamont PP, Rijnders CAT, Renier WO, et al. Anxiety and mood disorders in narcolepsy: a case-control study. Gen Hosp Psychiatry. 2010;32:49\u201356.","journal-title":"Gen Hosp Psychiatry"},{"key":"429_CR61","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.5665\/sleep.4910","volume":"38","author":"M Lecendreux","year":"2015","unstructured":"Lecendreux M, Lavault S, Lopez R, Inocente CO, Konofal E, Cortese S, et al. Attention-deficit\/hyperactivity disorder (ADHD) symptoms in pediatric narcolepsy: a cross-sectional study. Sleep. 2015;38:1285\u201395.","journal-title":"Sleep"},{"key":"429_CR62","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/sleep\/33.5.689","volume":"33","author":"G Plazzi","year":"2010","unstructured":"Plazzi G, Ferri R, Antelmi E, Bayard S, Franceschini C, Cosentino FII, et al. Restless legs syndrome is frequent in narcolepsy with cataplexy patients. Sleep. 2010;33:689\u201394.","journal-title":"Sleep"},{"key":"429_CR63","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2869.2007.00601.x","volume":"16","author":"Y Dauvilliers","year":"2007","unstructured":"Dauvilliers Y, Pennestri M-H, Petit D, Dang-Vu T, Lavigne G, Montplaisir J. Periodic leg movements during sleep and wakefulness in narcolepsy. J Sleep Res. 2007;16:333\u20139.","journal-title":"J Sleep Res"},{"key":"429_CR64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.sleep.2006.06.003","volume":"8","author":"B Abril","year":"2007","unstructured":"Abril B, Carlander B, Touchon J, Dauvilliers Y. Restless legs syndrome in narcolepsy: a side effect of sodium oxybate? Sleep Med. 2007;8:181\u20133.","journal-title":"Sleep Med"},{"key":"429_CR65","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5664\/jcsm.27716","volume":"6","author":"R Hoque","year":"2010","unstructured":"Hoque R, Chesson AL. Pharmacologically induced\/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder\/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med. 2010;6:79\u201383.","journal-title":"J Clin Sleep Med"},{"key":"429_CR66","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540\u20135.","journal-title":"Sleep"},{"key":"429_CR67","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","volume":"2","author":"CH Bastien","year":"2001","unstructured":"Bastien CH, Valli\u00e8res A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med. 2001;2:297\u2013307.","journal-title":"Sleep Med"},{"key":"429_CR68","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","volume":"43","author":"JW Shaw","year":"2005","unstructured":"Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203\u201320.","journal-title":"Med Care"},{"key":"429_CR69","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1073\/pnas.0400590101","volume":"101","author":"M Mieda","year":"2004","unstructured":"Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A. 2004;101:4649\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"429_CR70","doi-asserted-by":"crossref","first-page":"14239","DOI":"10.1523\/JNEUROSCI.3878-07.2007","volume":"27","author":"SA Deadwyler","year":"2007","unstructured":"Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci Off J Soc Neurosci. 2007;27:14239\u201347.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"429_CR71","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbr.2013.12.045","volume":"262","author":"SL Weinhold","year":"2014","unstructured":"Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, G\u00f6der R, Baier PC. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res. 2014;262:8\u201313.","journal-title":"Behav Brain Res"},{"key":"429_CR72","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/acs.jmedchem.5b00988","volume":"58","author":"T Nagahara","year":"2015","unstructured":"Nagahara T, Saitoh T, Kutsumura N, Irukayama-Tomobe Y, Ogawa Y, Kuroda D, et al. Design and synthesis of non-peptide, selective orexin receptor 2 agonists. J Med Chem. 2015;58:7931\u20137.","journal-title":"J Med Chem"},{"key":"429_CR73","doi-asserted-by":"crossref","first-page":"e95342","DOI":"10.1371\/journal.pone.0095342","volume":"9","author":"O Arias-Carri\u00f3n","year":"2014","unstructured":"Arias-Carri\u00f3n O, Murillo-Rodr\u00edguez E. Effects of hypocretin\/orexin cell transplantation on narcoleptic-like sleep behavior in rats. PLoS One. 2014;9:e95342.","journal-title":"PLoS One"},{"key":"429_CR74","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1474-4422(14)70218-2","volume":"14","author":"RS Liblau","year":"2015","unstructured":"Liblau RS, Vassalli A, Seifinejad A, Tafti M. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol. 2015;14:318\u201328. A recent analysis of current knowledge about neurobiology of narcolepsy.","journal-title":"Lancet Neurol"},{"key":"429_CR75","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.5665\/sleep.2870","volume":"36","author":"S Kantor","year":"2013","unstructured":"Kantor S, Mochizuki T, Lops SN, Ko B, Clain E, Clark E, et al. Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice. Sleep. 2013;36:1129\u201338.","journal-title":"Sleep"},{"key":"429_CR76","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.20339","volume":"56","author":"Y Dauvilliers","year":"2004","unstructured":"Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol. 2004;56:905\u20138.","journal-title":"Ann Neurol"},{"key":"429_CR77","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00415-008-0983-7","volume":"255","author":"G Plazzi","year":"2008","unstructured":"Plazzi G, Poli F, Franceschini C, Parmeggiani A, Pirazzoli P, Bernardi F, et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol. 2008;255:1549\u201354.","journal-title":"J Neurol"},{"key":"429_CR78","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/npp.2009.3","volume":"34","author":"S Hasan","year":"2009","unstructured":"Hasan S, Pradervand S, Ahnaou A, Drinkenburg W, Tafti M, Franken P. How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion. Neuropsychopharmacology. 2009;34:1625\u201340.","journal-title":"Neuropsychopharmacology"},{"key":"429_CR79","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.sleep.2015.05.013","volume":"16","author":"RK Bogan","year":"2015","unstructured":"Bogan RK, Feldman N, Emsellem HA, Rosenberg R, Lu Y, Bream G, et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16:1102\u20138. A phase II study that showed the efficacy of a new wake promoting agent (with dopaminergic and noradrenergic activity) on both objective and subjective daytime sleepiness in narcolepsy.","journal-title":"Sleep Med"},{"key":"429_CR80","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.5665\/sleep.5854","volume":"39","author":"A Duch\u00eane","year":"2016","unstructured":"Duch\u00eane A, Perier M, Zhao Y, Liu X, Thomasson J, Chauveau F, et al. Impact of astroglial connexins on modafinil pharmacological properties. Sleep. 2016;39:1283\u201392.","journal-title":"Sleep"},{"key":"429_CR81","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.neuropharm.2013.04.019","volume":"75","author":"X Liu","year":"2013","unstructured":"Liu X, Petit J-M, Ezan P, Gyger J, Magistretti P, Giaume C. The psychostimulant modafinil enhances gap junctional communication in cortical astrocytes. Neuropharmacology. 2013;75:533\u20138.","journal-title":"Neuropharmacology"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0429-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-016-0429-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0429-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T11:27:41Z","timestamp":1601033261000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-016-0429-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,22]]},"references-count":81,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1007\/s11940-016-0429-y","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,22]]},"article-number":"43"}}